1. Singapore Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Haw Par Corporation Limited

Haw Par Corporation Limited

12.76
SGD
-0.16
(-1.24%)
2.17BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.65
0.7
0.82
0.92
1.01
1.08
1.1
0.5
0.64
0.82
1.05
1.11
1.04
- -
Basic EPS, GAAP
0.49
0.54
0.84
0.57
0.56
0.81
0.82
0.54
0.5
0.67
0.98
1.03
1.2
- -
Free Cash Flow per Basic Share
0.42
0.25
0.56
0.4
0.28
0.3
0.37
0.08
0.07
0.1
0.25
0.23
0.25
- -
Dividend per Share
0.19
0.2
0.2
0.39
0.2
0.25
1.15
0.3
0.3
0.3
0.35
0.4
1.4
1.15
Book Value per Share
11.18
12.82
11.57
10.6
13.98
13.26
14.28
13.04
14.51
16.03
15.7
18.74
19.38
11.96
Tangible Book Value per Share
11.13
12.77
11.52
10.55
13.93
13.21
14.23
12.99
14.46
15.98
15.65
18.69
19.33
11.91
Basic Weighted Avg Shares
219
219
219
219
220
221
221
221
221
221
221
221
221
221
Sales/Revenue/Turnover
141
154
179
202
223
238
244
111
141
182
232
245
230
- -
Operating Margin (%)
26.49
27.87
29.79
35.75
32.18
35.01
32.35
12.55
17.49
23.82
27.58
26.08
29.17
- -
Depreciation Expense
5
5
5
3
6
6
6
7
6
6
6
6
6
- -
Net Income, GAAP
108
119
183
125
122
179
182
120
110
148
217
228
265
- -
Effective Tax Rate (%)
6.38
6.41
5.36
9.95
11.16
6.87
7.49
3.57
5.23
6.7
5.59
7.25
5.75
- -
Profit Margin (%)
76.44
77.05
102.48
62.01
54.97
75.3
74.68
107.87
77.99
81.45
93.32
93.24
115.43
- -
Working Capital
572
621
631
2,276
3,046
2,826
3,063
2,775
3,100
3,153
3,190
3,915
4,165
2,536
LT Debt
- -
- -
- -
46
45
- -
9
1
1
29
28
37
45
- -
Total Equity
2,445
2,807
2,535
2,325
3,078
2,928
3,156
2,885
3,211
3,549
3,476
4,149
4,291
2,645
Return on Invested Capital (%)
3.8
3.92
4.83
4.92
4.41
2.52
2.37
0.44
0.77
1.19
1.7
1.53
1.47
- -
Return on Capital (%)
4.56
4.47
6.75
5.02
4.4
5.86
5.96
3.96
3.61
4.38
6.16
5.96
6.21
- -
Return on Common Equity (%)
4.59
4.52
6.86
5.15
4.53
5.96
5.99
3.96
3.61
4.39
6.17
5.99
6.29
- -

Capital Structure

SGD

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
ST Debt
24
9
- -
LT Borrowings
24
8
- -
LT Finance Leases
- -
1
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
221
221
221
Market Capitalization
2,958
2,828
2,174

Working Capital

SGD

•

in mil. unless spec.
Sep'19
Dec'19
Jun'20
Total Current Assets
3,030
3,138
2,644
Cash, Cash Equivalents & STI
2,969
3,087
2,589
Accounts Receivable, Net
41
24
37
Inventories
19
20
18
Total Current Liabilities
102
75
107
Payables & Accruals
- -
- -
- -
ST Debt
24
9
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SGD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
8.51%
3.44%
Free Cash Flow
8.3%
37.85%
9.3%
Net Income, GAAP
7.42%
18.87%
16.29%
Sales/Revenue/Turnover
6.11%
16.6%
-6.07%
Total Cash Common Dividend
63.98%
56.21%
250%

Semi-annual Revenue

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
245
2025
- -
- -
230
2026
- -
- -
- -

Semi-annual Earnings Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
1.03
2025
- -
- -
1.2
2026
- -
- -
- -

Semi-annual Dividends Per Share

SGD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.4
2025
- -
- -
1.4
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ee Lim Wee
Full Time Employees
595
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 03-03 Haw Par Technocentre Singapore NW Singapore 149598
IPO Date
Jan 2, 1979
Website
hawpar.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Haw Par Corporation Limited is a Singapore-based conglomerate primarily engaged in the manufacture and sale of healthcare products, leisure and property investment. Its core business includes consumer healthcare products such as Tiger Balm ointments and plasters; pharmaceutical and wellness products encompassing medicated oils, capsules and topical analgesics; leisure services including theme parks operations such as the Tiger Balm Gardens; and property investments across Asia. The company operates mainly in Singapore, Malaysia, and other Southeast Asian markets. Founded in 1924 and headquartered in Singapore, Haw Par leverages its established brands and diversified portfolio to cater to both consumer healthcare and leisure segments. Recently, Haw Par Corporation has focused on digital transformation of its consumer products division and expanded its strategic partnerships with regional healthcare distributors to increase market penetration. It also intensified efforts in e-commerce platforms for its healthcare brands and launched new product variants to cater to evolving consumer preferences. Furthermore, the company has undertaken portfolio optimization by rationalizing non-core assets and investing selectively in high-growth segments within its leisure and healthcare businesses, aligning with its long-term growth strategy. Haw Par continues to explore strategic alliances and acquisition opportunities in Asia to enhance its market footprint and product offerings. The company operates through its subsidiaries and owns a portfolio of well-known healthcare brands with Tiger Balm as its flagship product. Haw Par's diversified business segments include consumer healthcare products, leisure, and property investment, targeting retail consumers, healthcare providers, and leisure visitors primarily in Southeast Asia but with expanding presence in adjacent regions. Its longstanding heritage and strong distribution network underpin its market leadership in the consumer medicated oil and ointment categories. In summary, Haw Par Corporation Limited is a leading Singaporean conglomerate specializing in healthcare consumer products, leisure, and property investments, with a history dating to 1924. It has recently undertaken strategic shifts emphasizing digital and regional expansion, product innovation, and portfolio streamlining to sustain growth and competitiveness in the Southeast Asian markets and beyond.